Drug Type Aptamer drug conjugates |
Synonyms Apc001PE, DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(3'¿3')-dT), 5'-ester with [[5-(phosphoonoxy) pentyl] amino] carbonyl-oxy-1, 2-ethanediyl, sodium salt, PEG40k conjugated Apc001 + [2] |
Target |
Mechanism SOST inhibitors(Sclerostin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Preclinical | HK | 30 Jan 2022 | |
Familial Hypophosphatemic Rickets | Preclinical | US | 30 Jan 2022 | |
Familial Hypophosphatemic Rickets | Preclinical | HK | 30 Jan 2022 | |
Osteogenesis Imperfecta | Preclinical | HK | 30 Jan 2022 | |
Osteoporosis | Preclinical | HK | 30 Jan 2022 | |
Triple Negative Breast Cancer | Preclinical | HK | 30 Jan 2022 |